Re: Chime in on this
Actually that is a simplification. The premise of a therapeutic index (the ratio of the toxic to therapeutic dose) is that the dose is therapeutic in the first place. In this case it can be argued the dose is not therapeutic.
In this instance ABUS demonstrated that LNP has a higher peak efficacy but shorter duration of action. Sc has a greater effect per mg, however, in a dosing that they thought was clinically usable had a lower peak effect that was more durable.
This also does not equate to everyone therefore using GalNAc. ABUS has been forthright about the comparison in a like per like experiment and expressed that sc is single trigger. It has also not stated that sc will replace LNP. To my, mind a combination may work best.
The fact that ARWR and others are using GalNAc is not isolated from the fact that they have no alternative.